<DOC>
	<DOCNO>NCT00874523</DOCNO>
	<brief_summary>To compare steady-state pharmacokinetics short-term efficacy safety two dose strategy raltegravir atazanavir virologically suppress HIV-infected adult receive atazanavir-containing combination antiretroviral therapy .</brief_summary>
	<brief_title>Raltegravir Atazanavir Dosing Strategy Study</brief_title>
	<detailed_description>Current HIV treatment guideline recommend construction combination regimens comprise minimum three agent least two drug class . There problem current recommendation although treatment effective , success often limited tolerability , adverse effect need take many pill . Antiretroviral adherence remain vital regimen simplify wherever possible facilitate maximal adherence . The recent availability potent HIV integrase inhibitor , raltegravir , provide opportunity explore move away current regimen component . Evidence support use novel regimen must generate adequately powered randomized clinical trial . However , trial undertake , preliminary data define pharmacokinetics , safety tolerability regimens need minimize unnecessary risk participant . This eight week study investigate steady-state pharmacokinetics , short-term safety efficacy two dosing strategy ( twice daily ) raltegravir plus atazanavir treatment experience HIV-infected adult .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>age â‰¥ 18 year laboratory evidence HIV1 infection currently receive 3 unchanged antiretroviral agent include atazanavir ( without ritonavir boost ) least 24 week prior study entry plasma HIV RNA le 50 copies/mL least 24 week prior study entry provide write , informed consent . Exclusion Criteria : prior clinical/virological failure PIcontaining regimen clinical history primary HIV1 protease mutation identify local baseline genotypic analysis HIV interpretation use current IASUSA Drug Resistance Mutations HIV1 woman : pregnant , breastfeeding , willing use adequate contraception ( include barrier contraception ) childbearing potential laboratory abnormality screen : absolute neutrophil count ( ANC ) &lt; 750 cells/mL haemoglobin le 8.5 g/dL platelet count less 50 000 cells/mL AST , ALT &gt; 5 time upper limit normal serum bilirubin &gt; 5 time upper limit normal chronic active hepatitis B infection define presence serum viral hepatitis B surface antigen ( HBsAg ) HBV DNApositive malabsorption syndrome likely affect drug absorption concurrent therapy human growth hormone immunomodulatory agent concomitant medication contraindicate use either atazanavir raltegravir therapy intercurrent illness require hospitalisation current excessive alcohol illicit substance use unlikely able remain followup protocoldefined period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>raltegravir</keyword>
	<keyword>atazanavir</keyword>
	<keyword>HIV infection</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>antiretroviral agent</keyword>
	<keyword>treatment experience</keyword>
</DOC>